Navigation Links
MiddleBrook Hires TalenTactics to Recruit National Field Force

GERMANTOWN, Md., Oct. 22 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has retained pharmaceutical recruiting firm TalenTactics LLC to lead its field force hiring effort in preparation for the Company's MOXATAG(TM) (amoxicillin extended-release tablets, 775mg) launch. The launch is targeted for the first half of 2009.

MiddleBrook President and CEO John Thievon commented, "TalenTactics served as a valuable partner for three Adams Respiratory Therapeutics sales force expansion projects, and its recruiting expertise in the healthcare space will be an invaluable asset to MiddleBrook. We plan to hire about 200 people for our national field force, which will lead our effort to inform healthcare practitioners about the important advantages of MOXATAG, the first and only FDA-approved once-daily amoxicillin."

"We are proud and delighted that MiddleBrook Pharmaceuticals has chosen TalenTactics to be their strategic partner in building this, their initial national sales force," stated George W. Scott, president of TalenTactics LLC. "MOXATAG and MiddleBrook's exciting pipeline represent an excellent opportunity for the people we will recruit into this sales force. We look forward to a mutually beneficial business relationship for years to come," he added.

Interested job applicants can find more information about the Company's open positions and apply online at the Careers section of MiddleBrook's web site,


MOXATAG (extended-release amoxicillin) 775mg tablets are a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components are combined in a specific ratio to prolong the release of amoxicillin from MOXATAG compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis.


MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in pulses are killed more efficiently than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit


TalenTactics is a pharmaceutical/ bio-pharmaceutical recruiting firm dedicated to the building, expansion, and maintenance of sales forces in the industry. To date TalenTactics has built upwards of 40 sales forces, large and small, and has placed over 5,000 sales and sales management professionals within the industry. Located in Conshohocken, PA, TalenTactics recruits nationally for pharmaceutical sales professionals and sales management talent from entry level to vice president levels.

This announcement contains forward-looking statements, within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time, and we assume no obligation to update any of these statements. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors" in our Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on October 17, 2008, and in our "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in our Annual Report on Form 10-K for the year ended Dec. 31, 2007. We urge you to review and consider the various disclosures made by us from time to time in our filings with the Securities and Exchange Commission, that attempt to advise you of the risks and factors that may affect our future results.

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
2. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
5. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
6. Alfacell Hires Advisors to Advance Strategic Alternatives
7. Symphony Managemnt Consulting Hires New Solutions Director
8. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
9. Informed Medical Communications Hires New Vice President of Marketing
10. Millstone Medical Outsourcing Achieves Quality Advantages in Memphis: Certified ISO 13485, Hires Experienced Quality Manager
11. MedThink Hires Two Executives to Serve its Growing Pharmaceutical Client Base
Post Your Comments:
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that ... that it has secured $25 million in a Series ... lead candidates SB-030 and SB-061. The financing was led ... existing major investors, as well as several new investors. ... Symic to over $43 million since being founded in ...
(Date:12/1/2015)... 1, 2015 ... "2016 U.K. Virology and Bacteriology Testing Market: ... Tests, Supplier Shares by Test, Innovative Technologies, ... offering.  --> ) has ... Virology and Bacteriology Testing Market: Sales and ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):